Delving into the Latest Updates on Chengdu New Radiomedicine Technology Co.,Ltd. with Synapse

Overview

Basic Info

Introduction

Based in Chengdu, Shuangliu, Chengdu Niuruite Medical Technology Co. Ltd specializes in the research, manufacture, and sale of medical isotopes. As a leading provider in China, they offer a variety of services including assistance with malignant tumor diagnoses, treatments, and the provision of radionuclides medical technology support, as well as consultations. The organization was established in April 2016 by three renowned co-founders.

Tags

Neoplasms

Digestive System Disorders

Endocrinology and Metabolic Disease

Small molecule drug

Recombinant polypeptide

Diagnostic radiopharmaceuticals

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Nervous System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	3
Diagnostic radiopharmaceuticals	2
Radionuclide Drug Conjugates (RDC)	2
Therapeutic radiopharmaceuticals	2
Radiopharmaceuticals and diagnostic agent	1

Top 5 Target	Count

FAP(Fibroblast activation protein alpha)	3
α-synuclein(Synuclein alpha)	1

Stage 1 (Safety study for 68Ga-NRT6020 Injection):
The goal of this clinical trial stage is to evaluate the safety of 68Ga-NRT6020 Injection in participants with advanced solid tumors. The study will also assess the biodistribution, radiation dosimetry, imaging profile, and pharmacokinetics of the drug. Additionally, researchers aim to investigate how consistent the PET/CT imaging results of 68Ga-NRT6020 are with 18F-FDG PET/CT imaging and FAP immunohistochemistry (IHC) results.
Stage 2 (Safety and tolerability study for 177Lu-NRT6020 Injection):
This stage focuses on evaluating the safety and tolerability of 177Lu-NRT6020 Injection in FAP-positive participants with advanced solid tumors. Researchers will also assess the safety of 68Ga-NRT6020 Injection in this population. The study will evaluate the biodistribution, radiation dosimetry, pharmacokinetics, and preliminary efficacy of 177Lu-NRT6020 Injection. Additionally, the imaging profile of 68Ga-NRT6020 and its consistency with other imaging techniques will be further investigated.
Stage 3 (Preliminary efficacy study for 68Ga/177Lu-NRT6020 Injection):
The objective of this stage is to evaluate the safety of 177Lu-NRT6020 Injection and 68Ga-NRT6020 Injection in FAP-positive participants with advanced solid tumors, as well as to determine the recommended phase 2 dose (RP2D) of 177Lu-NRT6020 Injection. The study will also assess the preliminary efficacy, biodistribution, radiation dosimetry, and pharmacokinetics of the drugs. Furthermore, researchers will investigate the imaging profile of 68Ga-NRT6020 and its consistency with other imaging techniques.

Start Date29 Nov 2025

Sponsor / Collaborator

Chengdu New Radiomedicine Technology Co.,Ltd.

NCT06900543

/ RecruitingPhase 3

A Randomized, Open-label, Multicenter Study Comparing the Efficacy and Safety of NRT6003 Injection With Conventional Transarterial Chemoembolization (cTACE) in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.

Start Date15 Apr 2025

Sponsor / Collaborator

Chengdu New Radiomedicine Technology Co.,Ltd.

NCT06278454

/ RecruitingPhase 1

A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of NRT6008 Injection in Unresectable Locally Advanced Pancreatic Cancer (LAPC)

This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study. And the independent review committee (IRC) will be formed to monitor efficacy data through the study.

Start Date09 Jan 2024

Sponsor / Collaborator

Chengdu New Radiomedicine Technology Co.,Ltd.

100 Clinical Results associated with Chengdu New Radiomedicine Technology Co.,Ltd.

Login to view more data

0 Patents (Medical) associated with Chengdu New Radiomedicine Technology Co.,Ltd.

Login to view more data

7

Literatures (Medical) associated with Chengdu New Radiomedicine Technology Co.,Ltd.

01 Sep 2025·JOURNAL OF RADIOLOGICAL PROTECTION

Study on concrete activation characteristics and safety management strategies for 30 MeV medical cyclotrons

Article

Author: Li, Min ; Liu, Zheng ; Rong, Maokai ; Ding, Yuan

Abstract:

This study systematically analyses the concrete activation problem and associated radiation risk caused by long-term operation of medical cyclotron. The research shows that medium energy (10–30 MeV) medical cyclotrons under high current operating conditions can induce concrete activation with penetration depths of 100–120 cm, mainly producing long-lived radionuclides such as Eu-152 and Co-60 with activity concentrations up to 600 Bq g−1 and 250 Bq g−1, respectively. Under operation at maximum design parameters, the peak ambient dose equivalent rate around the target chamber reaches 961 μSv h−1 at the end of operation and remains above 500 μSv h−1 even after two years of cooling, posing significant radiation risks to personnel. China’s current radiation safety management system faces the twin challenges of a lack of standards and insufficient radioactive waste management capacity. Based on international practices such as IAEA, recommendations are proposed to improve the management system in three dimensions: revision of regulations and standards, financial safeguards, and technological innovation.

01 Dec 2023·Bioorganic & medicinal chemistry

Biocompatible conjugated polymer nanoparticles labeled with 225Ac for tumor endoradiotherapy

Article

Author: Bai, Chiyao ; Ma, Huan ; Yang, Jijun ; Xiong, Yao ; Liang, Ranxi ; Liao, Jiali ; Liu, Ning ; Yang, Yuanyou ; Chen, Xijian ; Liu, Weihao ; Lan, Tu ; Li, Feize

Recently, endoradiotherapy based on actinium-225 (²²⁵Ac) has attracted increasing attention, which is due to its α particles can generate maximal damage to cancer cells while minimizing unnecessary radiation effects on healthy tissues. Herein, ¹¹¹In/²²⁵Ac-radiolabeled conjugated polymer nanoparticles (CPNs) coated with amphiphilic polymer DSPE-PEG-DOTA have been developed as a new injectable nano-radiopharmaceuticals for cancer endoradiotherapy under the guidance of nuclear imaging. Single photon emission computed tomography/computed tomography (SPECT/CT) using ¹¹¹In-DOTA-PEG-CPNs as nano probe indicates a prolonged retention of radiolabeled nanocarriers, which was consistent with the in vivo biodistribution examined by direct radiometry analysis. Significant inhibition of tumor growth has been observed in murine 4T1 models treated with ²²⁵Ac-DOTA-PEG-CPNs when compared to mice treated with PBS or DOTA-PEG-CPNs. The ²²⁵Ac-DOTA-PEG-CPNs group experienced no single death within 24 days with the median survival considerably extended to 35 days, while all the mice treated with PBS or DOTA-PEG-CPNs died at 20 days post injection. Additionally, the histopathology studies demonstrated no obvious side effects on healthy tissues after treatment with ²²⁵Ac-DOTA-PEG-CPNs. All these results reveal that the new ²²⁵Ac-labeled DOTA-PEG-CPNs is promising as paradigm for endoradiotherapy.

01 Mar 2019·Nuclear medicine and biologyQ4 · MEDICINE

A radiopharmaceutical [89Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo

Q4 · MEDICINE

Article

Author: Yang, Yuanyou ; Chen, Lin ; Hu, Yingjiang ; Yang, Jijun ; Ma, Huan ; Cai, Jiming ; Liao, Jiali ; Tang, Yu ; Zhao, Yan ; Liu, Ning ; Chen, Yue ; Liu, Weihao

INTRODUCTION:

The potential of the positron-emitting zirconium-89 (⁸⁹Zr) (t_1/2 = 78.4 h) has been recently reported for immune positron emission tomography (immunoPET) radioimmunoconjugates design. In our work, we explored the optimized preparation of [⁸⁹Zr]Zr-DFO-nimotuzumab, and evaluated ⁸⁹Zr-labeled monoclonal antibody (mAb) construct for targeted imaging of epidermal growth factor receptor (EGFR) overexpressed in glioma.

METHODS:

To optimize the radiolabeling efficiency of ⁸⁹Zr with DFO-nimotuzumab, multiple immunoconjugates and radiolabeling were performed. Radiolabeling yield, radiochemical purity, stability, and activity assay were investigated to characterize [⁸⁹Zr]Zr-DFO-nimotuzumab for chemical and biological integrity. The in vivo behavior of this tracer was studied in mice bearing subcutaneous U87MG (EGFR-positive) tumors received a 3.5 ± 0.2 MBq/dose using PET/CT imaging. One group mice bearing subcutaneous U87MG (EGFR-positive) tumors received [⁸⁹Zr]Zr-DFO-nimotuzumab (3.5 ± 0.2 MBq, ~3 μg) (nonblocking) for immunoPET; the other group had 30 μg predose (blocking) of cold nimotuzumab 24 h prior to [⁸⁹Zr]Zr-DFO-nimotuzumab.

RESULTS:

[⁸⁹Zr]Zr-DFO-nimotuzumab was prepared with high radiochemical yield (>90%), radiochemical purity (>99%), and specific activity (115 ± 0.8 MBq/mg). In vitro validation showed that [⁸⁹Zr]Zr-DFO-nimotuzumab had an initial immunoreactive fraction of 0.99 ± 0.05 and remained active for up to 5 days. A biodistribution study revealed excellent stability of [⁸⁹Zr]Zr-DFO-nimotuzumab in vivo compared with ⁸⁹Zr as a bone seeker. High uptake in the liver and heart and modest penetration in the brain were observed, with no significant accumulation of activity in other organs. ImmunoPET studies also indicated prominent image contrast that remarkably high uptake up to ~20%ID/g for nonblocking and ~2%ID/g for blocking in tumor between 12 and 120 h after administration.

CONCLUSION:

These studies developed a radiopharmaceutical [⁸⁹Zr]Zr-DFO-nimotuzumab with optimized synthesis. The potential utility of [⁸⁹Zr]Zr-DFO-nimotuzumab in assessing EGFR status in glioma was demonstrated in this study.

100 Deals associated with Chengdu New Radiomedicine Technology Co.,Ltd.

Login to view more data

100 Translational Medicine associated with Chengdu New Radiomedicine Technology Co.,Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Preclinical

Phase 1

3

1

Phase 3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NRT6008	Pancreatic carcinoma non-resectable More	Phase 1
177Lu-NRT6020 ( FAP )	Advanced Malignant Solid Neoplasm More	Phase 1
68Ga-NRT6020 ( FAP )	Advanced Malignant Solid Neoplasm More	Phase 1
[18F]Cou-NNF ( α-synuclein )	Neurodegenerative Diseases More	Preclinical
WO2024165072 ( FAP )Patent Mining	Neoplasms More	Discovery